Bioscience Americas Outlines Growth Strategy
Opportunities abound for the world's leading developer of autologous stem cell treatment centers.
Phoenix, AZ, July 19, 2016 --(PR.com)-- Bioscience Americas, LLC, the international development partner of the Global Institute of Stem Cell Therapy and Research (GIOSTAR), announced today that it projects a first quarter 2017 opening of its flagship stem cell treatment center at San Vicente Hospital in Rionegro, Colombia, South America.
Bioscience Americas, along with GIOSTAR, have partnered with San Vicente to bring FDA approved treatment protocols to patients in the Western Hemisphere suffering from devastating autoimmune diseases including multiple sclerosis, diabetes, Lou Gehrig’s Disease, and many others.
In addition to receiving patients from throughout South America, the San Vicente facility will also attract medical tourism patients North America and the world.
Bioscience Americas CEO Eric Stoffers, in commenting on the Company’s opportunities, said that they “have been approached by representatives of various nations and independent investment groups to develop additional centers internationally.” Potential future locations include Costa Rica, Mexico, the United Arab Emirates, Vietnam, and sovereign tribal land in the United States and Canada.
In addition to providing treatments for autoimmune diseases, the Company is also ramping up its Bioscience High Performance division for the treatment of orthopedic injuries from facilities to be located in the United States. Mr. Stoffers indicated that there are now more than 108 million Americans over the age of 50 including 76 million baby boomers. “As people age, they will come to rely on the therapies and treatments we offer through FDA sanctioned patient clinical studies,” Mr. Stoffers said.
He added that Bioscience High Performance will also offer treatments to amateur and professional athletes here in the United States and from throughout the world. “Right now,” he said, “U.S. athletes are travelling to Europe and elsewhere for orthopedic stem cell treatments. With Bioscience High Performance there will no longer be a need for them to travel for treatments.”
Bioscience Americas President Bill Deegan noted that the orthopedic market represents a significant opportunity for the Company. “Active Americans are more susceptible to orthopedic injuries. More than 100 million Americans work out on a regular basis and more than 20 million actively participate in organized sports activities. At some point, they will suffer an injury that will require our services,” he said.
Mr. Deegan added that the Company has also made inroads with professional sports teams to provide treatments for those whose livelihood depends on being injury free.
Bioscience Americas is completing a $15 million capital raise under SEC Regulation D, Rule 506 (c). Proceeds of the private placement offering will be used to fund the development of up to three stem cell treatment facilities. The facilities will employ only autologous, or adult, stem cell protocols developed by its science partner GIOSTAR.
GIOSTAR is a world-wide consortium of renowned research scientists and is based at the University of California Medical Center in San Diego. It maintains research affiliations with other leading universities and research centers throughout the world. It has been the recipient of more than $400 million in research funding throughout the last fifteen years and has treated close to 5,000 patients at its facility in India.
San Vicente Hospital is one of the largest hospitals in South America. It services more than 50,000 patients a year including more than 700 organ transplant patients.
For more information about Bioscience Americas please visit its website www.bioscienceamericas.com.
Bioscience Americas, along with GIOSTAR, have partnered with San Vicente to bring FDA approved treatment protocols to patients in the Western Hemisphere suffering from devastating autoimmune diseases including multiple sclerosis, diabetes, Lou Gehrig’s Disease, and many others.
In addition to receiving patients from throughout South America, the San Vicente facility will also attract medical tourism patients North America and the world.
Bioscience Americas CEO Eric Stoffers, in commenting on the Company’s opportunities, said that they “have been approached by representatives of various nations and independent investment groups to develop additional centers internationally.” Potential future locations include Costa Rica, Mexico, the United Arab Emirates, Vietnam, and sovereign tribal land in the United States and Canada.
In addition to providing treatments for autoimmune diseases, the Company is also ramping up its Bioscience High Performance division for the treatment of orthopedic injuries from facilities to be located in the United States. Mr. Stoffers indicated that there are now more than 108 million Americans over the age of 50 including 76 million baby boomers. “As people age, they will come to rely on the therapies and treatments we offer through FDA sanctioned patient clinical studies,” Mr. Stoffers said.
He added that Bioscience High Performance will also offer treatments to amateur and professional athletes here in the United States and from throughout the world. “Right now,” he said, “U.S. athletes are travelling to Europe and elsewhere for orthopedic stem cell treatments. With Bioscience High Performance there will no longer be a need for them to travel for treatments.”
Bioscience Americas President Bill Deegan noted that the orthopedic market represents a significant opportunity for the Company. “Active Americans are more susceptible to orthopedic injuries. More than 100 million Americans work out on a regular basis and more than 20 million actively participate in organized sports activities. At some point, they will suffer an injury that will require our services,” he said.
Mr. Deegan added that the Company has also made inroads with professional sports teams to provide treatments for those whose livelihood depends on being injury free.
Bioscience Americas is completing a $15 million capital raise under SEC Regulation D, Rule 506 (c). Proceeds of the private placement offering will be used to fund the development of up to three stem cell treatment facilities. The facilities will employ only autologous, or adult, stem cell protocols developed by its science partner GIOSTAR.
GIOSTAR is a world-wide consortium of renowned research scientists and is based at the University of California Medical Center in San Diego. It maintains research affiliations with other leading universities and research centers throughout the world. It has been the recipient of more than $400 million in research funding throughout the last fifteen years and has treated close to 5,000 patients at its facility in India.
San Vicente Hospital is one of the largest hospitals in South America. It services more than 50,000 patients a year including more than 700 organ transplant patients.
For more information about Bioscience Americas please visit its website www.bioscienceamericas.com.
Contact
Bioscience Americas
Bill Deegan
480-454-7996
www.bioscienceamericas.com
Bill Deegan
480-454-7996
www.bioscienceamericas.com
Contact
Categories